Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference

SAN RAMON, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
November 20, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline

SAN RAMON, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
November 09, 2015 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business

Clinical development immunotherapy programs make significant advances with new trials including a NeuVax™ Phase 2 clinical trial in DCIS and encouraging Phase 2a data for...
November 09, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

SAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
November 06, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN RAMON, Calif., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
October 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer

SAN RAMON, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
October 26, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015

SAN RAMON, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...
October 22, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences

SAN RAMON, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
September 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

PORTLAND, Ore., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
September 28, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015

GALE-301 is well-tolerated and elicits a strong and dose-dependent in vivo immune response; 1000 mcg identified as optimal dose In the 1000 mcg vaccine dose group (VG), the clinical...